Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (476) 476
Publication (32) 32
Book Review (12) 12
Book Chapter (4) 4
Magazine Article (4) 4
Conference Proceeding (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (330) 330
index medicus (248) 248
quinazolines - therapeutic use (203) 203
female (145) 145
lung neoplasms - drug therapy (124) 124
carcinoma, non-small-cell lung - drug therapy (121) 121
oncology (120) 120
male (119) 119
quinazolines - economics (106) 106
antineoplastic agents - therapeutic use (102) 102
quinazolines - pharmacology (102) 102
erlotinib hydrochloride (97) 97
middle aged (91) 91
chemotherapy (87) 87
quinazolines - administration & dosage (87) 87
aged (82) 82
erlotinib (77) 77
cancer (72) 72
gefitinib (70) 70
chemistry, organic (66) 66
cost-benefit analysis (65) 65
treatment outcome (65) 65
animals (63) 63
adult (60) 60
pharmacology & pharmacy (58) 58
protein kinase inhibitors - therapeutic use (57) 57
quinazolines - adverse effects (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
care and treatment (55) 55
antineoplastic agents - economics (54) 54
quinazolines - chemistry (51) 51
lung cancer (47) 47
analysis (45) 45
lung neoplasms - pathology (44) 44
derivatives (43) 43
carcinoma, non-small-cell lung - pathology (42) 42
mutation (42) 42
carcinoma, non-small-cell lung - economics (41) 41
lung cancer, non-small cell (41) 41
lung neoplasms - economics (41) 41
quinazolines (41) 41
receptor, epidermal growth factor - antagonists & inhibitors (41) 41
aged, 80 and over (40) 40
disease-free survival (40) 40
quinazoline (40) 40
research (40) 40
therapy (40) 40
chemistry, medicinal (36) 36
protein kinase inhibitors - economics (36) 36
inhibitors (35) 35
breast neoplasms - drug therapy (34) 34
drug costs (33) 33
growth-factor receptor (33) 33
receptor, epidermal growth factor - genetics (33) 33
quinazolines - chemical synthesis (32) 32
randomized controlled trials as topic (32) 32
respiratory system (31) 31
trial (31) 31
antineoplastic agents - pharmacology (30) 30
docetaxel (30) 30
drug therapy (30) 30
survival analysis (30) 30
breast cancer (29) 29
chemistry, multidisciplinary (29) 29
survival (29) 29
lung neoplasms - mortality (28) 28
non-small cell lung cancer (28) 28
antineoplastic combined chemotherapy protocols - economics (27) 27
carcinoma, non-small-cell lung - mortality (27) 27
deoxycytidine - analogs & derivatives (26) 26
hematology, oncology and palliative medicine (26) 26
medicine & public health (26) 26
quality-adjusted life years (26) 26
lung neoplasms - genetics (25) 25
antineoplastic agents (24) 24
antineoplastic agents - adverse effects (24) 24
medicine, general & internal (24) 24
quinazoline derivatives (24) 24
time factors (24) 24
colorectal neoplasms - drug therapy (23) 23
epidermal growth factor (23) 23
molecular structure (23) 23
trastuzumab (23) 23
united states (23) 23
adenocarcinoma - drug therapy (22) 22
carcinoma, non-small-cell lung - genetics (22) 22
cell lung-cancer (22) 22
metastasis (22) 22
neoplasm staging (22) 22
adenocarcinoma (21) 21
cancer therapies (21) 21
cost-effectiveness (21) 21
egfr (21) 21
open-label (21) 21
phase-iii trial (21) 21
synthesis (21) 21
antimitotic agents (20) 20
antineoplastic agents - administration & dosage (20) 20
biochemistry & molecular biology (20) 20
clinical trials as topic (20) 20
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States
by Ting, Jie, PhD, MSPH and Tien Ho, PharmD and Xiang, Pin, PharmD and Sugay, Amanda, PharmD and Abdel-Sattar, Maher, PharmD and Wilson, Leslie, PhD
Value in Health, ISSN 1098-3015, 2015, Volume 18, Issue 6, pp. 774 - 782
Abstract Objectives To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for... 
Internal Medicine | EGFR mutation-positive NSCLC | cost-effectiveness | treatment | value-of-information | expected value of perfect information | METAANALYSIS | ADENOCARCINOMA | ASIAN PATIENTS | OPEN-LABEL | CHEMOTHERAPY | ECONOMIC BURDEN | RANDOMIZED PHASE-3 TRIAL | DECISION-MAKING | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | EFFECTIVENESS ACCEPTABILITY CURVES | ECONOMICS | INHIBITORS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Models, Economic | Protein Kinase Inhibitors - adverse effects | Erlotinib Hydrochloride - economics | Clinical Trials, Phase III as Topic | Comparative Effectiveness Research | Pemetrexed - economics | Time Factors | Quinazolines - administration & dosage | Quality-Adjusted Life Years | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Protein Kinase Inhibitors - economics | Cisplatin - economics | Molecular Targeted Therapy - economics | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pemetrexed - administration & dosage | Quality of Life | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolines - economics | Drug Costs | Markov Chains | Uncertainty | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cisplatin - administration & dosage | Patient Selection | Antineoplastic Combined Chemotherapy Protocols - economics | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Decision Support Techniques | Erlotinib Hydrochloride - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Randomized Controlled Trials as Topic | Carcinoma, Non-Small-Cell Lung - economics | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Quinazolines - adverse effects | Cisplatin - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
by Hill, Andrew and Gotham, Dzintars and Fortunak, Joseph and Meldrum, Jonathan and Erbacher, Isabelle and Martin, Manuel and Shoman, Haitham and Levi, Jacob and Powderly, William G and Bower, Mark
BMJ Open, ISSN 2044-6055, 01/2016, Volume 6, Issue 1, p. e009586
ObjectiveTo calculate sustainable generic prices for 4 tyrosine kinase inhibitors (TKIs).BackgroundTKIs have proven survival benefits in the treatment of... 
MEDICINE, GENERAL & INTERNAL | IMPACT | ACCESS | Niacinamide - analogs & derivatives | Global Health - economics | Protein Kinase Inhibitors - economics | Humans | Niacinamide - economics | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Commerce | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - economics | Imatinib Mesylate - economics | Neoplasms - drug therapy | Erlotinib Hydrochloride - economics | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Drug Industry - economics | Sorafenib | Erlotinib Hydrochloride - therapeutic use | Lapatinib | Phenylurea Compounds - economics | Quinazolines - economics | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non-Small-Cell Lung Cancer
by Wang, Siying and Peng, Liubao and Li, Jianhe and Zeng, Xiaohui and Ouyang, Lihui and Tan, Chongqing and Lu, Qiong
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, p. e55917
Introduction: Lung cancer, the most prevalent malignant cancer in the world, remains a serious threat to public health. Recently, a large number of studies... 
PHASE-III TRIAL | GENE-MUTATIONS | GROWTH-FACTOR RECEPTOR | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | 2ND-LINE TREATMENT | ECONOMIC OUTCOMES | OPEN-LABEL | GEFITINIB THERAPY | COMBINATION | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Costs and Cost Analysis | Deoxycytidine - administration & dosage | Humans | Carboplatin - administration & dosage | Male | Models, Economic | Deoxycytidine - economics | Carboplatin - economics | Carcinoma, Non-Small-Cell Lung - economics | Time Factors | Antineoplastic Combined Chemotherapy Protocols - economics | Female | Quinazolines - administration & dosage | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Far East | Deoxycytidine - analogs & derivatives | Tyrosine | Economic aspects | Cost benefit analysis | Lung cancer, Non-small cell | Chemotherapy | Erlotinib | Gene mutations | Analysis | Markov processes | Genetic aspects | Health aspects | Medical care, Cost of | Cancer | Health care | Parameter estimation | Gemcitabine | Lung cancer | Clinical trials | Markov chains | Parameter sensitivity | Cancer therapies | Epidermal growth factor | Platinum | Parameter uncertainty | Protein-tyrosine kinase | Pharmaceutical sciences | Public health | Sensitivity analysis | Statistical analysis | Life expectancy | Small cell lung carcinoma | Epidermal growth factor receptors | Health risks | Non-small cell lung carcinoma | Patients | Hospitals | Pharmacy | Point mutation | Carboplatin | Mutation | Cost analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis
by Hill, Andrew and Redd, Christopher and Gotham, Dzintars and Erbacher, Isabelle and Meldrum, Jonathan and Harada, Ryo
BMJ Open, ISSN 2044-6055, 01/2017, Volume 7, Issue 1, p. e011965
ObjectivesThe aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could... 
PUBLIC HEALTH | THERAPEUTICS | 1ST-LINE TREATMENT | COUNTRIES | GUIDELINES | BIOSIMILARS | DASATINIB | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | MEDICINE, GENERAL & INTERNAL | ECONOMIC-EVALUATION | ONCOLOGY | HEALTH ECONOMICS | DRUGS | DOSE IMATINIB | CLINICAL PHARMACOLOGY | Drug Costs | Neoplasms - economics | Bortezomib - economics | Everolimus - economics | Humans | Dasatinib - therapeutic use | Dasatinib - economics | Drugs, Generic - economics | England | Commerce | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - economics | Neoplasms - drug therapy | Algorithms | Bortezomib - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Everolimus - therapeutic use | Quinazolines - economics | Gefitinib | Competition | Market entry | Lung cancer | Leukemia | Multiple myeloma | Licenses | Systematic review | Breast cancer | Metastasis | Epidemiology | Cancer therapies | Exports | Prices | Hepatitis | Intellectual property | Manufacturing | Cost analysis | Drug dosages | Public health | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cost‐effectiveness of epidermal growth factor receptor mutation testing and first‐line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by de Lima Lopes, Gilberto and Segel, Joel E and Tan, Daniel S. W and Do, Young K and Mok, Tony and Finkelstein, Eric A
Cancer, ISSN 0008-543X, 02/2012, Volume 118, Issue 4, pp. 1032 - 1039
BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming... 
cost‐effectiveness | gefitinib | economic evaluation | Asia | epidermal growth factor receptor | lung adenocarcinoma | cost-effectiveness | MULTICENTER | TYROSINE KINASE | CANCER | CHEMOTHERAPY | EGFR | IRESSA | ONCOLOGY | INHIBITOR | ERLOTINIB | PREVIOUSLY TREATED PATIENTS | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Singapore | Adenocarcinoma of Lung | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | ErbB Receptors - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Bevacizumab | Glutamates - economics | Antibodies, Monoclonal, Humanized - economics | Adenocarcinoma - genetics | Cetuximab | Gefitinib | Guanine - therapeutic use | Lung Neoplasms - genetics | Quality-Adjusted Life Years | Pharmacogenetics | Antibodies, Monoclonal, Humanized - therapeutic use | Guanine - economics | Treatment Outcome | Mutation - genetics | Adenocarcinoma - drug therapy | Pemetrexed | Antineoplastic Agents - economics | Quinazolines - therapeutic use | Cost-Benefit Analysis | Genetic Testing - economics | Quinazolines - economics | Antibodies, Monoclonal - economics | Adenocarcinoma - mortality | Adenocarcinoma | Dosage and administration | Planning | Drug therapy | Medical care, Cost of
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer
by Narita, Yusuke and Matsushima, Yukiko and Shiroiwa, Takeru and Chiba, Koji and Nakanishi, Yoichi and Kurokawa, Tatsuo and Urushihara, Hisashi
Lung Cancer, ISSN 0169-5002, 2015, Volume 90, Issue 1, pp. 71 - 77
Highlights • Cost-effectiveness of first-line gefitinib therapy with EGFR testing is examined using Markov model. • Combination use of gefitinib and EGFR... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Pharmacoeconomics | Cost-effectiveness analysis | Individualized medicine | Gefitinib | Non-small cell lung cancer | ONCOLOGY | RESPIRATORY SYSTEM | ADENOCARCINOMA | PHASE-III | OPEN-LABEL | CHEMOTHERAPY | GEMCITABINE | DNA Mutational Analysis - economics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Markov Chains | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - pathology | DNA Mutational Analysis - methods | Young Adult | Antineoplastic Combined Chemotherapy Protocols - economics | Adult | Quinazolines - administration & dosage | Paclitaxel - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Economics, Pharmaceutical | Paclitaxel - economics | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Decision Support Techniques | Carboplatin - administration & dosage | Carboplatin - economics | Carcinoma, Non-Small-Cell Lung - economics | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Cost-Benefit Analysis | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - economics | Analysis | Pharmacy | Markov processes | Drugstores | Cost benefit analysis | Lung cancer, Non-small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
by Thomas E. Delea and Paul Tappenden and Oleg Sofrygin and Dominy Browning and Mayur M. Amonkar and Jon Karnon and Mel D. Walker and David Cameron
The European Journal of Health Economics, ISSN 1618-7598, 10/2012, Volume 13, Issue 5, pp. 589 - 603
Background In a phase III trial of women with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab, an anthracycline, and taxanes... 
Health care costs | Chemotherapy | Sensitivity analysis | Cost estimation models | Cost estimates | Utilities costs | Experimentation | Medications | Breast cancer | Cost efficiency | Economics | Cost and cost analysis | Economic Policy | Medicine & Public Health | Statistics for Life Sciences, Medicine, Health Sciences | Statistics for Business/Economics/Mathematical Finance/Insurance | I1 | Public Finance & Economics | Health Informatics | Breast neoplasms, secondary | Public Health/Gesundheitswesen | Lapatinib | Secondary | Breast neoplasms | SURVIVAL | UNITED-KINGDOM | CARE | TRIAL | GROWTH-FACTOR RECEPTOR | UNCERTAINTY | HEALTH POLICY & SERVICES | EXPERIENCE | PROGRESSION | Confidence Intervals | State Medicine | Women's Health | Breast Neoplasms - economics | Capecitabine | Humans | Fluorouracil - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Antibodies, Monoclonal, Humanized - economics | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Female | Drug Therapy, Combination | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Probability | Antimetabolites, Antineoplastic - economics | United Kingdom | Deoxycytidine - economics | Breast Neoplasms - drug therapy | Antineoplastic Agents - economics | Antimetabolites, Antineoplastic - therapeutic use | Breast Neoplasms - psychology | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - economics | Deoxycytidine - analogs & derivatives | Trastuzumab | Studies | Economic models | Health care expenditures | Epidermal growth factor | Economic theory | Metastasis | Cost analysis | Economic statistics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
by Lange, Ansgar and Prenzler, Anne and Frank, Martin and Golpon, Heiko and Welte, Tobias and von der Schulenburg, J.-Matthias
BMC Pulmonary Medicine, ISSN 1471-2466, 12/2014, Volume 14, Issue 1, pp. 192 - 192
Background: Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems and society due to increasing incidence and poor... 
Crizotinib | Cost-effectiveness analysis | Health economics | Afatinib | Erlotinib | Targeted therapy | Non-small cell lung cancer | Cost-utility analysis | Monoclonal antibody | Gefitinib | Tyrosine kinase inhibitors | Bevacizumab | 1ST-LINE TREATMENT | PROSPECTIVE PHASE-2 | MAINTENANCE THERAPY | CHEMOTHERAPY | SUPPORTIVE CARE | RESPIRATORY SYSTEM | COLORECTAL-CANCER | 2ND-LINE TREATMENT | ECONOMIC-ANALYSIS | Lung Neoplasms - drug therapy | Bevacizumab - administration & dosage | Protein Kinase Inhibitors - economics | Humans | Erlotinib Hydrochloride - administration & dosage | Lung Neoplasms - pathology | Molecular Targeted Therapy - economics | Erlotinib Hydrochloride - economics | Protein Kinase Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Antineoplastic Combined Chemotherapy Protocols - economics | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Antibodies, Monoclonal - economics | Bevacizumab - economics | Tyrosine | Monoclonal antibodies | Metastasis | Cost benefit analysis | Lung cancer, Non-small cell | Medical care, Cost of
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
by Carlson, Josh J and Garrison, Louis P and Ramsey, Scott D and Veenstra, David L
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 1, pp. 20 - 27
Abstract Objectives Pharmacogenomic applications in oncology offer significant promise, but the clinical and economic implications remain unclear. The... 
Internal Medicine | lung cancer | cost-utility | economic evaluation | docetaxel | erlotinib | pharmacogenetics | cost‐utility | Pharmacogenetics | Erlotinib | Lung cancer | Cost-utility | Docetaxel | Economic evaluation | GEFITINIB | GROWTH-FACTOR-RECEPTOR | CHEMOTHERAPY | PHASE-III TRIAL | BREAST-CANCER | SUPPORTIVE CARE | PROTEIN EXPRESSION | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | GENE COPY NUMBER | Erlotinib Hydrochloride | Quality-Adjusted Life Years | Lung Neoplasms - drug therapy | Protein Kinase Inhibitors - economics | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Non-Small-Cell Lung - economics | Pharmacogenetics - economics | Taxoids - therapeutic use | Genes, erbB-1 | Taxoids - economics | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Decision Trees | Quinazolines - economics | Care and treatment | Epidermal growth factor | Oncology, Experimental | Development and progression | Flexible response (Strategy) | Research | Deterrence (Strategy) | Lung cancer, Non-small cell | Health aspects | Medical care, Cost of | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Economics of Treatments for Non-Small Cell Lung Cancer
by Chouaid, Christos and Atsou, Kukovi and Hejblum, Gilles and Vergnenegre, Alain
PharmacoEconomics, ISSN 1170-7690, 2009, Volume 27, Issue 2, pp. 113 - 125
The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness... 
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | COST-MINIMIZATION ANALYSIS | SUPPORTIVE CARE | COMPARING GEMCITABINE/CISPLATIN | VINORELBINE PLUS CISPLATIN | CHEMOTHERAPY REGIMENS | CLINICAL-TRIALS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | GUIDELINES 2ND EDITION | QUALITY-OF-LIFE | HOSPITAL COSTS | Erlotinib Hydrochloride | Carcinoma, Non-Small-Cell Lung - radiotherapy | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - surgery | Guanine - analogs & derivatives | Humans | Guanine - economics | Lung Neoplasms - radiotherapy | Pemetrexed | Combined Modality Therapy - economics | Glutamates - economics | Carcinoma, Non-Small-Cell Lung - economics | Taxoids - therapeutic use | Taxoids - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Antineoplastic Combined Chemotherapy Protocols - economics | Lung Neoplasms - surgery | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Guanine - therapeutic use | Chemotherapy | Care and treatment | Economic aspects | Diagnosis | Radiotherapy | Lung cancer, Non-small cell | Health aspects | Cancer | Studies | Health care expenditures | Health economics | Lung cancer | Medical treatment | Life Sciences | Taxoids | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Santé publique et épidémiologie | Combined Modality Therapy | Quinazolines | Glutamates | Lung Neoplasms | Guanine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
by Borget, Isabelle and Pérol, Maurice and Pérol, David and Lavolé, Armelle and Greillier, Laurent and Dô, Pascal and Westeel, Virginie and Crequit, Jacky and Léna, Hervé and Monnet, Isabelle and Le Caer, Hervé and Fournel, Pierre and Falchero, Lionel and Poudenx, Michel and Vaylet, Fabien and Chabaud, Sylvie and Vergnenegre, Alain and Zalcman, Gérard and Chouaïd, Christos and IFCT-GFPC Investigators and IFCT-GFPC investigators
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, p. 953
Background: The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation... 
Non-small-cell lung cancer | Erlotinib | Gemcitabine | Maintenance therapy | Cost-utility | PLACEBO | CARBOPLATIN | BEVACIZUMAB | 1ST-LINE CHEMOTHERAPY | CELL LUNG-CANCER | TRIAL | SUPPORTIVE CARE | ONCOLOGY | DOUBLE-BLIND | AMERICAN SOCIETY | PLUS | Erlotinib Hydrochloride | Induction Chemotherapy - economics | Lung Neoplasms - drug therapy | Prospective Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Adult | Female | Quinazolines - administration & dosage | Quality-Adjusted Life Years | Deoxycytidine - administration & dosage | Cisplatin - economics | Deoxycytidine - economics | Antineoplastic Agents - economics | Carcinoma, Non-Small-Cell Lung - economics | Health Care Costs | Cost-Benefit Analysis | Survival Analysis | Maintenance Chemotherapy - economics | Aged | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Deoxycytidine - analogs & derivatives | Life Sciences | Medication | Pharmaceutical sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The economic evaluation of personalised oncology medicines: ethical challenges
by Lewis, Jan R R and Lipworth, Wendy L and Kerridge, Ian H and Day, Richard O
Medical Journal of Australia, ISSN 0025-729X, 10/2013, Volume 199, Issue 7, pp. 471 - 473
Summary Insights into the molecular drivers of cancer are providing opportunities for the development of new targeted treatments and more personalised... 
Economics | Neoplasms | CELL LUNG-CANCER | CARBOPLATIN-PACLITAXEL | SURVIVAL | TRIAL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | MULTICENTER | EGFR MUTATION | OPEN-LABEL | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | ErbB Receptors - antagonists & inhibitors | Neoplasms - economics | Randomized Controlled Trials as Topic - methods | Humans | Precision Medicine - economics | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - economics | Precision Medicine - ethics | Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - economics | Quinazolines - therapeutic use | Cost-Benefit Analysis | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Australia | Gefitinib | Bioethics | Evaluation | Drugs (Pharmaceuticals) | Health economics | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
by Lu, Shun and Ye, Ming and Ding, Lieming and Tan, Fenlai and Fu, Jie and Wu, Bin
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 6, pp. 9996 - 10006
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell... 
EGFR mutation | Icotinib | Gefitinib | Cost-effectiveness | Non-small cell lung cancer | non-small cell lung cancer | cost-effectiveness | MULTICENTER | ADENOCARCINOMA | gefitinib | OPEN-LABEL | PHASE-3 | NETWORK METAANALYSIS | MAINTENANCE THERAPY | CELL BIOLOGY | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | ERLOTINIB | icotinib | PLUS | Drug Costs | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Precision Medicine - economics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Models, Economic | Protein Kinase Inhibitors - adverse effects | Crown Ethers - therapeutic use | Pemetrexed - economics | Time Factors | China | Computer Simulation | Antineoplastic Combined Chemotherapy Protocols - economics | Crown Ethers - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Quality-Adjusted Life Years | Lung Neoplasms - enzymology | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Crown Ethers - economics | Molecular Targeted Therapy - economics | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolines - economics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights